3.54
-1.94%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aquestive Therapeutics
From its filings with the US Securities and Exchange Commission
Aquestive Therapeutics is based in Warren, New Jersey and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker AQST. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $44.5m and a net loss of $83.8m. At that date it held total assets of $160.4m and shareholders' equity of −$33.7m.
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. We are developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. We are advancing our late stage non-device based epinephrine prodrug product candidate for the treatment of severe allergic reactions, including anaphylaxis, under the "Anaphylm™" trade name, and our AdrenaVerse™ epinephrine prodrug pipeline platform. We have four licensed commercialized products which are marketed by our licensees in the U.S. and around the world. We are the exclusive manufacturer of these licensed products. Aquestive also collaborates with pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven drug development and commercialization capabilities. Our production facilities are located in Portage, Indiana, and our corporate headquarters and primary research laboratory facilities are based in Warren, New Jersey.
Quoted from its 10-K, filed 4 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 25 Jul 2018
- Employees
- 147
- Website
- aquestive.com ↗
- Head office
- 184 LIBERTY CORNER ROAD, WARREN, NJ
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Gregory BrownIndependent Chairman of the Board$198,500
- Mr. Daniel BarberPresident, Chief Executive Officer, Director, since 2014$4.2m
- Mr. John CochranIndependent Vice Chairman of the Board$156,609
- Mr. A. Ernest TothChief Financial Officer$1.1m
- Ms. Cassie JungChief Operating Officer
- Mr. Peter BoydSenior Vice President - Information Technology, Human Resources and Communications
- Dr. Melina CioffiSenior Vice President - Regulatory Affairs
- Ms. Lori BraenderChief Legal Officer, Chief Compliance Officer and Corporate Secretary$1.8m
- Ms. Sherry KorczynskiChief Commercial Officer
- Dr. Carl KrausChief Medical Officer
- Mrs. Abigail JenkinsIndependent Director$190,230
- Dr. Julie KropIndependent Director$167,344
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 32
- Environment
- 15
- Social
- 31
- Governance
- 50
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Aquestive Therapeutics Inc possesses several strengths that contribute to its success in the industry. Firstly, the company has a strong portfolio of innovative and proprietary pharmaceutical products, allowing it to cater to a wide range of therapeutic areas. This diverse product portfolio provides Aquestive Therapeutics Inc with a competitive edge in the market.
- Furthermore, the company boasts a highly experienced and talented research and development team. Their expertise allows Aquestive Therapeutics Inc to continually develop and enhance its products, driving innovation and ensuring the company stays at the forefront of medical advancements.
- Additionally, Aquestive Therapeutics Inc has established strategic partnerships and collaborations with key industry players. These partnerships grant the company access to additional resources, expertise, and distribution channels, enabling greater market reach and potential for growth.
Weaknesses
- Aquestive Therapeutics Inc also faces certain weaknesses that may pose challenges to its operations and growth. One weakness is the company's heavy reliance on a limited number of products for its revenue generation. This dependency exposes Aquestive Therapeutics Inc to the risk of declining revenues if any of these key products face regulatory issues or market competition.
- Additionally, the company is relatively small in size compared to some of its competitors. This may limit its resources and capabilities to effectively compete on a global scale, especially in terms of marketing, distribution, and research and development investments.
Opportunities
- Aquestive Therapeutics Inc operates in an industry with several promising opportunities. One significant opportunity lies in the growing demand for effective therapies in various therapeutic areas. As the global population continues to face health challenges, there is an increasing need for innovative pharmaceutical products and treatment solutions, which Aquestive Therapeutics Inc can capitalize on.
- Additionally, the company can explore expansion into international markets, leveraging its existing partnerships and collaborations to access new customers and gain a competitive advantage. This expansion can help diversify revenue streams and reduce reliance on a single market.
Threats
- Aquestive Therapeutics Inc operates in an industry that is highly regulated and subject to intense competition. This poses a threat to the company's market position and profitability. Aquestive Therapeutics Inc needs to stay compliant with evolving regulations and stay ahead of the competition by continually investing in research and development and maintaining product superiority.
- Another threat to the company is the potential for patent expirations or challenges from generic drug manufacturers. Aquestive Therapeutics Inc needs to actively protect its intellectual property rights and effectively manage patent expirations to preserve its market share and revenue streams.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.